80 related articles for article (PubMed ID: 27510662)
1. Do phosphatase of regenerating liver-3, matrix metalloproteinases-2, matrix metalloproteinases-9, and epidermal growth factor receptor-1 predict response to therapy and survival in glioblastoma multiforme?
Soni P; Husain N; Chandra A; Ojha BK; Bhatt ML; Gupta RK
Indian J Pathol Microbiol; 2016; 59(3):287-93. PubMed ID: 27510662
[TBL] [Abstract][Full Text] [Related]
2. Revisiting epidermal growth factor receptor in glioblastoma multiforme: does it play a role in response to therapy?
Soni P; Husain N; Awasthi R; Chandra A; Ojha BK; Gupta RK
Indian J Pathol Microbiol; 2014; 57(3):390-5. PubMed ID: 25118729
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.
Heimberger AB; Hlatky R; Suki D; Yang D; Weinberg J; Gilbert M; Sawaya R; Aldape K
Clin Cancer Res; 2005 Feb; 11(4):1462-6. PubMed ID: 15746047
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme.
Quan AL; Barnett GH; Lee SY; Vogelbaum MA; Toms SA; Staugaitis SM; Prayson RA; Peereboom DM; Stevens GH; Cohen BH; Suh JH
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):695-703. PubMed ID: 15936158
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors.
Layfield LJ; Willmore C; Tripp S; Jones C; Jensen RL
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):91-6. PubMed ID: 16540738
[TBL] [Abstract][Full Text] [Related]
6. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
7. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
8. Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Wallin AR; Svanvik J; Adell G; Sun XF
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):452-8. PubMed ID: 16626893
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and pathological significance of p53 gene mutation in human cerebral glioblastoma multiforme].
Matsumoto R
Hokkaido Igaku Zasshi; 1998 Jul; 73(4):407-17. PubMed ID: 9828926
[TBL] [Abstract][Full Text] [Related]
10. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunohistochemical prognostic factors in adult glioblastoma patients.
Umesh S; Tandon A; Santosh V; Anandh B; Sampath S; Chandramouli BA; Sastry Kolluri VR
Clin Neuropathol; 2009; 28(5):362-72. PubMed ID: 19788052
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
[TBL] [Abstract][Full Text] [Related]
13. The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme.
Brzozowska A; Toruń A; Mazurkiewicz M
Adv Clin Exp Med; 2015; 24(2):279-87. PubMed ID: 25931361
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group.
Chakravarti A; Seiferheld W; Tu X; Wang H; Zhang HZ; Ang KK; Hammond E; Curran W; Mehta M
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):318-27. PubMed ID: 15890570
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
16. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
Mineo JF; Bordron A; Baroncini M; Ramirez C; Maurage CA; Blond S; Dam-Hieu P
Acta Neurochir (Wien); 2007 Mar; 149(3):245-52; discussion 252-3. PubMed ID: 17273889
[TBL] [Abstract][Full Text] [Related]
17. Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Hatate K; Yamashita K; Hirai K; Kumamoto H; Sato T; Ozawa H; Nakamura T; Onozato W; Kokuba Y; Ihara A; Watanabe M
Oncol Rep; 2008 Oct; 20(4):737-43. PubMed ID: 18813812
[TBL] [Abstract][Full Text] [Related]
18. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients.
Ganigi PM; Santosh V; Anandh B; Chandramouli BA; Sastry Kolluri VR
Pediatr Neurosurg; 2005; 41(6):292-9. PubMed ID: 16293948
[TBL] [Abstract][Full Text] [Related]
19. Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.
Seidlitz A; Siepmann T; Löck S; Juratli T; Baumann M; Krause M
Radiat Oncol; 2015 Aug; 10():172. PubMed ID: 26276734
[TBL] [Abstract][Full Text] [Related]
20. Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.
Adeberg S; Bostel T; Harrabi S; Bernhardt D; Welzel T; Wick W; Debus J; Combs SE
BMC Cancer; 2015 Jul; 15():558. PubMed ID: 26223282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
